First Trust Health Care AlphaDEX Fund (FXH) Valuation
FXH valuation today
Holdings combined · company data as of Oct 26, 2026- P/E (TTM)
- 29.3 trailing earnings
- Forward P/E
- 14.7 analyst estimates
- Price / sales
- 1.66
- Price / book
- 3.56
- EV / EBITDA
- 12.0
- Earnings yield
- 3.42% inverse of P/E
- Dividend yield
- 0.69% of the holdings
- Return on equity
- 12.2% combined
- Net margin
- 5.7% combined
- Beta
- 0.81 weighted, vs S&P 500
FXH valuation vs other stock ETFs
| ETF | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE | Net margin | Loss-makers |
|---|---|---|---|---|---|---|---|---|
| FXH | 29.3 | 14.7 | 1.66 | 3.56 | 0.69% | 12.2% | 5.7% | 15.5% |
| SPY | 25.9 | 19.9 | 3.67 | 5.47 | 1.08% | 21.1% | 14.2% | 1.9% |
| QQQ | 34.2 | 23.4 | 5.93 | 9.27 | 0.58% | 27.1% | 17.4% | 6.9% |
| DIA | 20.9 | 18.4 | 3.16 | 5.52 | 1.55% | 26.4% | 15.1% | 0.0% |
| VTI | 28.2 | 19.4 | 3.31 | 5.00 | 1.07% | 17.7% | 11.8% | 4.6% |
| IWM | n/m | 13.9 | 1.25 | 2.03 | 1.38% | −1.7% | −1.0% | 28.1% |
Same method for every fund. n/m = not meaningful (combined trailing earnings below zero or close to it). Loss-makers = weight of holdings with negative trailing earnings.
FXH valuation by sector
| Sector | Weight | P/E | Fwd P/E | P/S | P/B | Div. yield | ROE |
|---|---|---|---|---|---|---|---|
| Healthcare | 99.6% | 29.3 | 14.7 | 1.66 | 3.56 | 0.69% | 12.2% |
FXH earnings yield vs bond yields
Earnings yield = earnings ÷ price (1 ÷ P/E). The gap to bond yields is a rough gauge of the extra return stocks are priced to deliver.
How FXH weight splits by P/E
Share of the covered weight in companies with a trailing P/E in each range.
FXH largest holdings: valuation
| Symbol | Company | Weight | P/E | Fwd P/E | P/S | Div. yield | Share of earnings |
|---|---|---|---|---|---|---|---|
| CNC | Centene Corporation | 2.71% | — | 11.2 | 0.2 | — | −12.02% |
| HALO | Halozyme Therapeutics, Inc. | 2.60% | 35.6 | 11.5 | 8.3 | — | 2.15% |
| CI | Cigna Corporation | 2.58% | 12.5 | 8.3 | 0.3 | 2.06% | 6.06% |
| GMED | Globus Medical, Inc. | 2.56% | 19.7 | 13.9 | 3.3 | — | 3.83% |
| ZBH | Zimmer Biomet Holdings, Inc. | 2.49% | 23.1 | 10.1 | 2.1 | 1.01% | 3.17% |
| MEDP | Medpace Holdings, Inc. | 2.48% | 36.3 | 31.9 | 6.2 | — | 2.00% |
| UHS | Universal Health Services, Inc. | 2.38% | 7.6 | 7.3 | 0.6 | 0.43% | 9.20% |
| CAI | Caris Life Sciences, Inc. | 2.35% | 18.1 | 43.3 | 8.7 | — | 3.81% |
| NTRA | Natera, Inc. | 2.22% | — | — | 20.9 | — | −0.22% |
| SOLV | Solventum Corporation | 2.19% | 10.5 | 13.1 | 1.8 | — | 6.14% |
| DXCM | DexCom, Inc. | 2.16% | 34.1 | 28.2 | 6.5 | — | 1.86% |
| ZTS | Zoetis Inc. | 2.15% | 13.1 | 12.0 | 3.4 | 2.67% | 4.83% |
| LLY | Eli Lilly and Company | 2.12% | 42.2 | 24.4 | 14.1 | 0.55% | 1.48% |
| CORT | Corcept Therapeutics Incorporated | 2.06% | 244.8 | 19.3 | 14.3 | — | 0.25% |
| REGN | Regeneron Pharmaceuticals, Inc. | 2.04% | 19.6 | 14.5 | 5.2 | 0.48% | 3.07% |
| EXEL | Exelixis, Inc. | 2.03% | 19.6 | 13.6 | 6.3 | — | 3.04% |
| GH | Guardant Health, Inc. | 2.03% | — | — | 18.0 | — | −1.31% |
| UTHR | United Therapeutics Corporation | 2.03% | 19.1 | 16.4 | 7.2 | — | 3.12% |
| THC | Tenet Healthcare Corporation | 2.02% | 10.5 | 12.5 | 1.0 | — | 5.64% |
| MDT | Medtronic plc | 1.97% | 23.3 | 14.9 | 3.2 | 3.04% | 2.49% |
| GEHC | GE HealthCare Technologies Inc. | 1.96% | 16.0 | 12.1 | 1.5 | 0.23% | 3.60% |
| COO | The Cooper Companies, Inc. | 1.93% | 19.9 | 11.3 | 2.6 | — | 2.84% |
| BSX | Boston Scientific Corporation | 1.91% | 18.0 | 13.2 | 3.1 | — | 3.12% |
| AMGN | Amgen Inc. | 1.91% | 26.9 | 16.7 | 6.1 | 2.33% | 2.09% |
| BMY | Bristol-Myers Squibb Company | 1.88% | 13.2 | 9.4 | 2.5 | 4.22% | 4.20% |
Share of earnings = the holding's part of the fund's combined trailing profit. Green: earns more than its weight; orange: less. Symbol links go to each company's key metrics.
About FXH valuation
Adding up its 71 holdings with company data, FXH trades at 29.3 times trailing earnings and 14.7 times analysts' forward estimates, with a price-to-book ratio of 3.56 and a dividend yield of 0.69%. Its earnings yield of 3.42% is 1.91 percentage points below the 5.33% yield to maturity of the U.S. bond market (AGG).
The ten largest holdings are 24.6% of the fund and earn 24.1% of its combined profit. Companies that lost money over the past year are 15.5% of the covered weight.
How these figures are calculated. Each ratio treats the fund as one company: the earnings, sales and book value of every holding are added up in proportion to its weight and divided into the fund's price. In practice that is a weighted harmonic mean, so a single stock with a very high P/E cannot distort the result, and loss-making companies reduce the fund's earnings instead of being dropped. Covers 100.0% of the fund's weight (U.S.-listed stocks with company data); company figures as of October 26, 2026.
Related: FXH chart, FXH performance, FXH holdings, FXH dividends.
FXH valuation FAQ
What is the P/E ratio of FXH?
Based on its holdings, FXH has a trailing P/E of 29.3 and a forward P/E of 14.7 (earnings of all covered holdings combined in proportion to their weights, as of October 26, 2026).
What is the earnings yield of FXH?
The trailing earnings yield is 3.42% (1 ÷ P/E) and the forward earnings yield 6.78%. For comparison the U.S. bond market (AGG) yields 5.33% to maturity and T-bills about 3.91%.
Is FXH more expensive than the S&P 500?
FXH trades at 29.3 times trailing earnings versus 25.9 for the S&P 500 (SPY); on forward estimates the figures are 14.7 and 19.9.
What is the price-to-book ratio of FXH?
The holdings of FXH trade at 3.56 times book value, with a combined return on equity of 12.2%.